A novel calcimimetic evocalcet for the management of secondary hyperparathyroidism with little effect on the gastrointestinal tract and cyp isozymes in vivo and in vitro release_abh72ntsmjdhfhfctic2kg5ixe

by Lilit Egshatyan

Entity Metadata (schema)

abstracts[] {'sha1': '29349158cbf6e1ef0c21c0f930a843211d2b2182', 'content': 'In the treatment of secondary hyperparathyroidism of end-stage chronic kidney disease, vitamin D receptor activation and allosteric modulators of the calcium-sensing receptor - inhibit glandular hyperplasia; reduce parathyroid hormone levels, impact on bone turnover and mineral density. Cinacalcet, an oral calcimimetic agent has been widely used for the management of secondary hyperparathyroidism in chronic kidney disease. Nevertheless, some patients remain refractory to the treatment, as the dose of cinacalcet cannot be sufficiently increased due to gastrointestinal symptoms and it strong inhibits of cytochrome P450 (CYP) 2D6. In order to resolve this issue, was develop a newly synthesized calcimimetic agent, evocalcet (MT-4580/KHK7580). In a rat model of chronic kidney disease induced by 5/6 nephrectomy, and in multicenter, open-label study phase 3, and in clinical practice oral administration of evocalcet efficiently suppressed the secretion of parathyroid hormone. Evocalcet also demonstrated the less induction of emesis and gastro-intestinal effects, and its pharmacological effects were observed at lower doses because of its higher bioavailability than cinacalcet. In addition, evocalcet showed no substantial direct inhibition of any CYP isozymes in in vitro. These findings suggest that evocalcet can be a better alternative to cinacalcet with a wider safety margin.', 'mimetype': 'application/xml+jats', 'lang': None}
container {'state': 'active', 'ident': 'e3gaqo4gnvddzpfxho6f7p7dta', 'revision': '64dcb2be-1fff-4821-91d4-9b3124c5754a', 'redirect': None, 'extra': {'country': 'ru', 'default_license': 'CC-BY-NC-ND', 'doaj': {'archive': ['LOCKSS', 'PKP PN'], 'as_of': '2022-07-06', 'default_license': 'CC-BY-NC-ND', 'seal': False}, 'kbart': {'pkp_pln': {'year_spans': [[2005, 2013], [2016, 2019]]}}, 'languages': ['en'], 'platform': 'ojs', 'publisher_type': 'longtail', 'urls': ['https://osteo.endojournals.ru/']}, 'edit_extra': None, 'name': 'Osteoporoz i osteopatii', 'container_type': None, 'publication_status': None, 'publisher': 'UP Print', 'issnl': '2072-2680', 'issne': '2311-0716', 'issnp': '2072-2680', 'wikidata_qid': 'Q96722895'}
container_id e3gaqo4gnvddzpfxho6f7p7dta
contribs[] {'index': 0, 'creator_id': 'hlok6jmj5vhgbnionktdau76ee', 'creator': {'state': 'active', 'ident': 'hlok6jmj5vhgbnionktdau76ee', 'revision': 'c0754b43-0adc-4775-80c6-baf4c62e84ab', 'redirect': None, 'extra': None, 'edit_extra': None, 'display_name': 'Lilit Egshatyan', 'given_name': 'Lilit', 'surname': 'Egshatyan', 'orcid': '0000-0001-8817-1901', 'wikidata_qid': None}, 'raw_name': 'Lilit V. Egshatyan', 'given_name': 'Lilit V.', 'surname': 'Egshatyan', 'role': 'author', 'raw_affiliation': None, 'extra': {'seq': 'first'}}
ext_ids {'doi': '10.14341/osteo12309', 'wikidata_qid': None, 'isbn13': None, 'pmid': None, 'pmcid': None, 'core': None, 'arxiv': None, 'jstor': None, 'ark': None, 'mag': None, 'doaj': None, 'dblp': None, 'oai': None, 'hdl': None}
files[] {'state': 'active', 'ident': '3gbhhq2svjh7tp6tvokwgiaqs4', 'revision': '2cec76ed-1d63-42c9-b3e7-6d6405fef55e', 'redirect': None, 'extra': None, 'edit_extra': None, 'size': 152192, 'md5': 'be648aeea4b58c73be78052e1f453ec7', 'sha1': 'bd68111326009693f0643b054d3dd4662fa08db0', 'sha256': '7474918a4ac687211db7feb56fd25ce526a0a60df9c9aaef81bab8fadfff4fcd', 'urls': [{'url': 'https://osteo-endojournals.ru/osteo/article/download/12309/pdf', 'rel': 'publisher'}, {'url': 'https://web.archive.org/web/20200603173841/https://osteo-endojournals.ru/osteo/article/download/12309/pdf', 'rel': 'webarchive'}], 'mimetype': 'application/pdf', 'content_scope': None, 'release_ids': ['abh72ntsmjdhfhfctic2kg5ixe'], 'releases': None}
{'state': 'active', 'ident': 'elojn3mrbzc6vgepwol6ukp3yy', 'revision': '83a47698-1781-43db-bdb4-7fdbe01aa711', 'redirect': None, 'extra': None, 'edit_extra': None, 'size': 195567, 'md5': '50a79766df211bddb5baa0ff4910df94', 'sha1': '0023e5a97c54e8cfd3f3f74901d81cf3f87910dd', 'sha256': '035ad96d10358b38eb2d8125aab77e19816f7325cccdfd85dcf5944a56a2dec1', 'urls': [{'url': 'https://www.osteo-endojournals.ru/jour/article/download/12309/pdf_2', 'rel': 'web'}, {'url': 'https://web.archive.org/web/20210428092103/https://www.osteo-endojournals.ru/jour/article/download/12309/pdf_2', 'rel': 'webarchive'}], 'mimetype': 'application/pdf', 'content_scope': None, 'release_ids': ['abh72ntsmjdhfhfctic2kg5ixe'], 'releases': None}
filesets []
issue
language
license_slug CC-BY-NC-ND
number
original_title
pages 27-33
publisher Endocrinology Research Centre
refs []
release_date 2020-06-01
release_stage published
release_type article-journal
release_year 2020
subtitle
title A novel calcimimetic evocalcet for the management of secondary hyperparathyroidism with little effect on the gastrointestinal tract and cyp isozymes in vivo and in vitro
version
volume 22
webcaptures []
withdrawn_date
withdrawn_status
withdrawn_year
work_id lzfct5bs7rbsnpwnagbo5lktue
As JSON via API

Extra Metadata (raw JSON)

crossref.license [{'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0', 'content-version': 'unspecified', 'delay-in-days': 0, 'start': '2020-06-01T00:00:00Z'}]
crossref.type journal-article